Abeona Therapeutics Inc. (NASDAQ:ABEO) shares traded up 4.1% during trading on Tuesday . The company traded as high as $2.56 and last traded at $2.51, with a volume of 137,567 shares traded. The stock had previously closed at $2.41.

A number of research analysts have recently commented on the company. Zacks Investment Research lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, June 1st. Rodman & Renshaw reiterated a “buy” rating and set a $17.00 price target on shares of Abeona Therapeutics in a report on Wednesday, April 20th. FBR & Co reiterated a “buy” rating on shares of Abeona Therapeutics in a report on Wednesday, June 22nd. Finally, Maxim Group reiterated a “buy” rating on shares of Abeona Therapeutics in a report on Tuesday, May 24th.

The stock’s 50 day moving average price is $2.68 and its 200-day moving average price is $2.66. The stock’s market cap is $81.33 million.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. On average, equities analysts predict that Abeona Therapeutics Inc. will post ($0.59) EPS for the current year.

An institutional investor recently raised its position in Abeona Therapeutics stock. Royce & Associates LLC increased its stake in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the SEC.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.